Consistent with the in vitro data, the miR-3180 inhibitor increased triglyceride and cholesterol levels in tumor tissues, while SCD1 or CD36 knockdown inhibited this effect (Additional file 1: Fig. S4). Here, CD36 is linked to neoplasm.